CO6251288A2 - Novedosas fenilpirrolidinas disustuidas como moduladores de la neurotransmision catecolaminergica cortical - Google Patents

Novedosas fenilpirrolidinas disustuidas como moduladores de la neurotransmision catecolaminergica cortical

Info

Publication number
CO6251288A2
CO6251288A2 CO09145364A CO09145364A CO6251288A2 CO 6251288 A2 CO6251288 A2 CO 6251288A2 CO 09145364 A CO09145364 A CO 09145364A CO 09145364 A CO09145364 A CO 09145364A CO 6251288 A2 CO6251288 A2 CO 6251288A2
Authority
CO
Colombia
Prior art keywords
phenylpirrolidins
novedosa
disenuted
catecolaminergic
neurotransmission
Prior art date
Application number
CO09145364A
Other languages
English (en)
Spanish (es)
Inventor
Clas Sonesson
Lars Swanson
Fredrik Petterson
Nicholas Waters
Susanna Waters
Original Assignee
Nsab Of Neurosearch Sweden Ab Severige
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nsab Of Neurosearch Sweden Ab Severige filed Critical Nsab Of Neurosearch Sweden Ab Severige
Publication of CO6251288A2 publication Critical patent/CO6251288A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12Oxygen or sulfur atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CO09145364A 2007-06-05 2009-12-18 Novedosas fenilpirrolidinas disustuidas como moduladores de la neurotransmision catecolaminergica cortical CO6251288A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94199407P 2007-06-05 2007-06-05
SE0701387 2007-06-05

Publications (1)

Publication Number Publication Date
CO6251288A2 true CO6251288A2 (es) 2011-02-21

Family

ID=39743744

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09145364A CO6251288A2 (es) 2007-06-05 2009-12-18 Novedosas fenilpirrolidinas disustuidas como moduladores de la neurotransmision catecolaminergica cortical

Country Status (16)

Country Link
US (1) US8188301B2 (enExample)
EP (1) EP2155671B8 (enExample)
JP (1) JP5444535B2 (enExample)
KR (1) KR20100038295A (enExample)
CN (1) CN101808987A (enExample)
AU (1) AU2008258599B2 (enExample)
BR (1) BRPI0812740A2 (enExample)
CA (1) CA2690091A1 (enExample)
CO (1) CO6251288A2 (enExample)
IL (1) IL202045A0 (enExample)
MX (1) MX2009012787A (enExample)
NZ (1) NZ581364A (enExample)
RU (1) RU2471781C2 (enExample)
UA (1) UA98783C2 (enExample)
WO (1) WO2008148801A2 (enExample)
ZA (1) ZA200908592B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8188301B2 (en) 2007-06-05 2012-05-29 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission
JP5716202B2 (ja) 2008-11-24 2015-05-13 インテグレイティブ・リサーチ・ラボラトリーズ・スウェーデン・アーベー 皮質のカテコールアミン作動性神経伝達のモジュレーターとしての3−フェニル−3−メトキシピロリジン誘導体
EP2367785B1 (en) 2008-11-24 2014-10-15 Integrative Research Laboratories Sweden AB Novel 3-phenyl-azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission
WO2010058020A1 (en) * 2008-11-24 2010-05-27 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Novel 1 -alkyl- 3 -hydroxy- 3 -phenylazetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission
SG171914A1 (en) 2008-12-02 2011-07-28 Chiralgen Ltd Method for the synthesis of phosphorus atom modified nucleic acids
TW201026666A (en) * 2008-12-16 2010-07-16 Astrazeneca Ab Quaternary piperidine derivatives and uses thereof
EP2451461A4 (en) 2009-07-06 2013-05-29 Ontorii Inc NOVEL NUCLEIC ACID PRODRUGS AND METHOD OF USE THEREOF
DK2620428T3 (da) * 2010-09-24 2019-07-01 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
US9605019B2 (en) 2011-07-19 2017-03-28 Wave Life Sciences Ltd. Methods for the synthesis of functionalized nucleic acids
CN112007045B (zh) 2012-07-13 2026-01-06 波涛生命科学有限公司 手性控制
DK2872485T3 (da) 2012-07-13 2021-03-08 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
JP6246121B2 (ja) 2012-07-13 2017-12-13 株式会社新日本科学 キラル核酸アジュバント
WO2015108048A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
US10322173B2 (en) 2014-01-15 2019-06-18 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
EP3095461A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
KR102423317B1 (ko) 2014-01-16 2022-07-22 웨이브 라이프 사이언시스 리미티드 키랄 디자인
EP3297987B1 (en) * 2015-05-20 2019-05-15 Integrative Research Laboratories Sweden AB Novel azetidine derivatives useful as modulators of cortical cathecolaminergic neurotransmission
ES2805031T3 (es) 2016-02-10 2021-02-10 Sumitomo Chemical Co Método de producción de 1-metilpirrolidin-3-ol
JP7126522B2 (ja) 2017-05-19 2022-08-26 インテグレイティブ・リサーチ・ラボラトリーズ・スウェーデン・アーベー (+)-3-(2,3-ジフルオロフェニル)-3-メトキシピロリジンまたはその薬学的に許容される塩、それを調製するための方法およびその使用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2878264A (en) 1959-03-17 Substituted amino alcohols
DE1144279B (de) 1957-09-26 1963-02-28 Robins Co Inc A H Verfahren zur Herstellung von 3-Aryl-3-hydroxypyrrolidinen und deren Salzen
US3118907A (en) * 1961-08-14 1964-01-21 Mead Johnson & Co 3-substituted-3-pyrrolidinols
BE704683A (enExample) 1966-11-07 1968-02-15
US3647790A (en) 1969-04-08 1972-03-07 American Home Prod Ouinoxalinyl-oxazolidines and -oxazines
US5128362A (en) 1988-01-15 1992-07-07 Abbott Laboratories 1-aminomethyl-1,2,3,4-tetrahydronaphthalenes
DE3802175A1 (de) 1988-01-26 1989-08-03 Hoechst Ag N-phenylbenzamide und n-phenylbenzamidoxime, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als schaedlingsbekaempfungsmittel
DE3835291A1 (de) * 1988-04-19 1989-11-02 Bayer Ag 1,3-disubstituierte pyrrolidine
US5444083A (en) * 1989-02-03 1995-08-22 Eisai Co., Ltd. Pyrrolidine compound and pharmaceutical use
ATE201669T1 (de) * 1991-04-17 2001-06-15 Upjohn Co Substituierte (s)-3-phenylpiperidin derivate, deren herstellung und deren verwendung als dopamin autorezeptor antagonisten
EP0586229A1 (en) * 1992-09-01 1994-03-09 Zeneca Limited 3-Hydroxy-3-(subst-akyl)-pyrrolidines as 5-lipoxygenase inhibitors
US5665754A (en) * 1993-09-20 1997-09-09 Glaxo Wellcome Inc. Substituted pyrrolidines
AU1208397A (en) 1995-12-28 1997-07-28 Takeda Chemical Industries Ltd. Diphenylmethane derivatives as mip-1alpha/rantes receptor antagonists
PL345283A1 (en) 1998-07-20 2001-12-03 Merck Patent Gmbh Biphenyl derivatives
US20020169155A1 (en) 1998-09-04 2002-11-14 Millennium Pharmaceuticals, Inc. Chemokine receptor anagonists and methods of use therefor
US7271176B2 (en) 1998-09-04 2007-09-18 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use thereof
DE19840611A1 (de) * 1998-09-05 2000-03-09 Klaus Wanner GABA-uptake-Inhibitoren mit Pyrrolidinstruktur
WO2000070531A2 (en) 1999-05-17 2000-11-23 The Foxboro Company Methods and apparatus for control configuration
ECSP003637A (es) 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
SE9904723D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission II
JP4765627B2 (ja) 2003-09-22 2011-09-07 Msd株式会社 新規ピペリジン誘導体
SE0401465D0 (sv) 2004-06-08 2004-06-08 Carlsson A Research Ab New substituted piperdines as modulators of dopamine neurotransmission
US7700587B2 (en) 2004-09-07 2010-04-20 Florida A&M University Haloperidol analogs
US7598279B2 (en) 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
US20090215742A1 (en) 2005-05-03 2009-08-27 Pfizer, Inc. Amide resorcinol compounds
WO2007053145A1 (en) 2005-11-04 2007-05-10 Florida A & M University Haloperidol analogs
ES2412007T3 (es) 2005-12-21 2013-07-09 Janssen Pharmaceutica, N.V. Derivados de pirazinona sustituida novedosos para uso en enfermedades mediadas por MCH-1
US8188301B2 (en) 2007-06-05 2012-05-29 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission
DE602008006720D1 (de) 2007-06-05 2011-06-16 Nsab, Filial Af Neurosearch Sweden Ab Neue disubstituierte phenylpyrrolidine als modulatoren der kortikalen katecholaminergen neurotransmission

Also Published As

Publication number Publication date
US20100179211A1 (en) 2010-07-15
WO2008148801A8 (en) 2009-12-10
AU2008258599B2 (en) 2013-06-13
RU2471781C2 (ru) 2013-01-10
RU2009143104A (ru) 2011-07-20
EP2155671A2 (en) 2010-02-24
KR20100038295A (ko) 2010-04-14
CA2690091A1 (en) 2008-12-11
UA98783C2 (en) 2012-06-25
EP2155671B1 (en) 2017-12-20
AU2008258599A1 (en) 2008-12-11
US8188301B2 (en) 2012-05-29
NZ581364A (en) 2011-10-28
IL202045A0 (en) 2010-06-16
WO2008148801A3 (en) 2009-01-29
MX2009012787A (es) 2009-12-15
CN101808987A (zh) 2010-08-18
JP2010529081A (ja) 2010-08-26
JP5444535B2 (ja) 2014-03-19
WO2008148801A2 (en) 2008-12-11
ZA200908592B (en) 2011-02-23
EP2155671B8 (en) 2018-02-21
BRPI0812740A2 (pt) 2016-07-19

Similar Documents

Publication Publication Date Title
AR106237A2 (es) Inhibidores heterocíclicos de la aspartil proteasa, sus sales farmacéuticamente aceptables
DOP2011000113A (es) Pirazolilaminopiridinas como inhibidores de fak
CY1110209T1 (el) Υποκατεστημενες ενωσεις βενζο(d)ισοξαζολ-3-υλ-αμινης σαν αναλγητικα
NO20080129L (no) Fremgangsmate for fremstilling av dihydrokinazoliner
AR074648A1 (es) Derivados de isoxazolina que poseen un anillo de cuatro miembros como grupo terminal, intermediarios de sintesis, composiciones biocidas que los contienen y metodos para combatir y controlar dichas plagas
EA200701176A1 (ru) Новые соединения нафталина, способ их получения и фармацевтические композиции, содержащие их
UY35641A (es) PROCEDIMIENTO DE SÍNTESIS PARA PREPARAR ANÁLOGOS MACROCÍCLICOS C1-CETO DE HALICONDRINA B, E INTERMEDIARIOS ÚTILES INCLUYENDO INTERMEDIARIOS CONTENIENDO GRUPOS ?SO2-(p-TOLILO)
TN2009000199A1 (en) Heteromonocyclic compound and use thereof
CO6210724A2 (es) Compuesto heterociclico y composicion farmaceutica del mismo
GEP201706792B (en) Synergistic compositions
AR077080A1 (es) Compuestos de 2,3-dihidro-1h-indeno
MX2011010451A (es) Derivados de oxadiazol.
ECSP109964A (es) Pirimidinas bicíclicas fusionadas
MX375556B (es) Compuestos de benzoxaborol tricíclicos y usos de los mismos.
MX2009007436A (es) Derivados espirociclicos de acido tetronico.
MX2015001099A (es) Nuevos derivados biciclicos de piridina.
AR112787A2 (es) Compuestos 1,5-difenil-penta-1,4-dien-3-ona
PL1891004T3 (pl) Pentafluorosulfanylo-podstawiony związek i jego zastosowanie do wytwarzania środków leczniczych
CR20130594A (es) Monohidrato de derivados de aza-adamantano
DOP2006000234A (es) Inhibidores de cinasa
CL2020000553A1 (es) Compuestos heteroaromáticos sustituidos con cicloolefinas y su uso.
NI201800065A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento de cáncer
AR065468A1 (es) Derivados de nevirapina inhibidores de la transcriptasa reversa
AR062131A1 (es) Profarmacos antimicrobianos de oxazolidinona
DOP2006000233A (es) Inhibidores de cinasa

Legal Events

Date Code Title Description
FC Application refused